Reflections on the Demand for PSMA- and SSTR-Targeted Radiopharmaceutical Therapies: Why We Were Wrong (and Why We Will Be Right Eventually)
Following the Food and Drug Administration’s approval of Lutathera and Pluvicto in 2018 and 2022, respectively, we predicted that 120,000 and 30,000 radiopharmaceutical therapy (RPT) cycles would soon be administered annually in the United States to treat prostate cancer (PC) and neuroendocrine
Authors
- Lisa Bodei (ORCID: https://orcid.org/0000-0001-6930-7383)
- Jérémie Calais (ORCID: https://orcid.org/0000-0002-8839-4379)
- Irvin M. Modlin
- Johannes Czernin
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Cornell University (US)
- Yale University (US)
- Molecular Theranostics (United States) (US)
Publication Details
- Journal
- Journal of Nuclear Medicine
- Published
- 2025-02-06
- DOI
- https://doi.org/10.2967/jnumed.124.269401
- Citations
- 1
- Primary Topic
- Radiopharmaceutical Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 1.36